An experimental Alzheimer’s drug outperforms one just approved by the FDA
A large study of an experimental Alzheimer's drug made by pharmaceutical company Eli Lilly & Co. appears to slow worsening of the degenerative brain disease. Darron Cummings/AP hide caption toggle caption Darron Cummings/AP A large study of an experimental Alzheimer's drug made by pharmaceutical company Eli Lilly & Co. appears to slow worsening of the…
Alzheimer’s drug Leqembi gets full FDA approval. Medicare coverage will likely...
The Food and Drug Administration has fully approved Leqembi, the first drug shown to slow down Alzheimer's disease. Andrew Harnik/AP hide caption toggle caption Andrew Harnik/AP The Food and Drug Administration has fully approved Leqembi, the first drug shown to slow down Alzheimer's disease. Andrew Harnik/AP The Food and Drug Administration has fully approved the…
An Alzheimer’s drug could soon be approved, but accessing it may...
The Food and Drug Administration may soon grant full approval to an Alzheimer's drug. When it does, Medicare will start more widely covering the costly drug — but hurdles to access remain.
An Alzheimer’s drug is on the way, but getting it may...
In patients with Alzheimer's disease, a substance called beta-amyloid can form toxic clumps in between neurons. Drugs like lecanemab are designed to remove amyloid-beta from the brain. National Institute on Aging, National Institutes of Health. hide caption toggle caption National Institute on Aging, National Institutes of Health. In patients with Alzheimer's disease, a substance called…
Scientists may be able to help Alzheimer’s patients by boosting memory...
Researchers say they've found a way to boost memories, which could help people struggling with memory loss from Alzheimer's disease or dementia. (Story aired on All Things Considered on June 1, 2023.) Health By boosting memory consolidation, scientists may be able to help Alzheimer's patients
FDA official behind Alzheimer’s drug scandal steps down
The Food and Drug Administration official who allegedly had an inappropriately cozy relationship with the maker of the controversial Alzheimer's drug, Aduhelm, is stepping down from his role, effective immediately, according to numerous media reports. Billy Dunn, head of the FDA's neuroscience office, has been with the agency for around 18 years, during which he…
Iowa Alzheimer’s care facility is fined $10,000 after pronouncing a living...
The sign for Glen Oaks Alzheimer's Special Care Center is seen on Google Earth. The facility pronounced a living woman dead and is being fined $10,000. Google Earth/Screenshot by NPR In early January, an Alzheimer's care facility in Iowa pronounced one of its residents dead. But when funeral home staff unzipped her body bag, she…
The FDA approves an Alzheimer’s drug that appears to modestly slow...
The FDA approves an Alzheimer's drug that appears to modestly slow the disease : NPR The FDA approves an Alzheimer's drug that appears to modestly slow the disease The Food and Drug Administration has approved an Alzheimer's drug that appears to modestly slow down the disease. (Story aired on Weekend Edition Saturday on Jan. 6,…
FDA approves new Alzheimer’s treatment despite risks, unclear benefits
Enlarge / MRI of a human brain. The Food and Drug Administration on Friday granted a fast-tracked approval for a new Alzheimer's disease treatment, which may slightly slow the progression of cognitive decline in the disease's early stages, but also raises risks of brain bleeds and swelling. The treatment—lecanemab, brand name Leqemb, made by pharmaceutical…
FDA approves Alzheimer’s drug that appears to modestly slow disease
U.S. health officials approved Leqembi, a new Alzheimer's drug that modestly slows the brain disease. The FDA granted accelerated approval Friday for patients in early stages of Alzheimer's. David Duprey/AP hide caption toggle caption David Duprey/AP U.S. health officials approved Leqembi, a new Alzheimer's drug that modestly slows the brain disease. The FDA granted accelerated…
